Protein produced by chronically infected cells in persons with HPV16 infection serves as a biomarker for risk of cancer of the oropharynx.
Prospective pilot study demonstrates accuracy of circulating tumor cells as a biomarker indicating lung cancer recurrence.
Novel diagnostic test determines whether suspicious lung lesions or nodules are malignant disease from a sample obtained via nasal swab.
A protocol of testing of CA125 levels quarterly with subsequent transvaginal ultrasound examination increased detection of early-stage ovarian cancer in women at high-risk for the disease.
Research presented at SABCS 2016 identified biomarkers predictive of response to trastuzumab-containing therapies in patients with HER2-positive breast cancer.
Expression of this hormone receptor may indicate a less aggressive subtype of triple-negative breast cancer and better prognosis for patients with the disease.
Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).
Genetic biomarkers from tumor DNA circulating in the bloodstream could indicate the risk for recurrence of colorectal cancer and the efficacy of chemotherapy after surgery.
Patients with kataegis, a recently discovered phenomenon in which multiple mutations cluster in a few hotspots in a genome, have less invasive tumors and better prognoses.
Analysis of proteins identified in urine has led to the discovery of proteomic signatures for prostate cancer that have the potential to serve as highly accurate noninvasive biomarkers that can identify aggressive disease before surgery.
Outcomes in Clinical Trials Using Precision Medicine Demonstrate Effectiveness of Modality in Patients With CancerJune 20, 2016
A meta-analysis of hundreds of cancer clinical trials revealed that therapeutic approaches using precision medicine had improved responses and longer disease remission, even in phase I trials.
Biochemical Marker Is a Better Predictor of Adverse Effects in Patients with Non-small Cell Lung CancerJune 13, 2016
Albumin concentration with an established cutoff point is proven a better predictor of both chemotherapy toxicity and survival in patients with advanced lung cancer.
The 2016 WHO Classification of Infiltrating Gliomas alters diagnostic criteria, providing the basis for clinical trial inclusion or exclusion based on an integrated diagnosis and setting the stage for all future research, according to a summary of 4 posters related to CNS biomarkers presented at the ASCO 2016 Annual Meeting.
Aggressive basal cell skin cancers have higher levels of both EZH2 and Ki67, suggesting these proteins have potential to serve as biomarkers for when basal cell carcinoma has become dangerous.
Disparities in the gut microbiome between healthy people and women with estrogen-driven breast cancer may indicate possible biomarkers based on the microbiome that could help to mitigate the risk of certain cancers.
[Biomarkers in Cancer] This research examines the emerging role of genomic rearrangements in breast cancer, with a particular focus on fusion genes, and explores the therapeutic value of such rearrangements and their significance as predictive and prognostic biomarkers.
Precision medicine aims to deliver the most appropriate treatment to individual patients; however, biomarker tests that are poorly validated or inappropriately applied could hinder administration of appropriate treatments, and in some cases motivate the use of harmful treatment.
A new biomarker measurement might improve the accuracy of prognostic testing and precision medicine in uveal melanoma.
Unique metabolic biomarkers specific to lung cancer were found through metabolic phenotyping of blood plasma by proton nuclear magnetic resonance (H-NMR), enabling diagnosis of both early-stage and late-stage disease.
A recently developed biomarker test for patients with advanced colorectal cancer could help determine the best treatment options for each patient.
A methylation signature was identified in 5 types of cancer, and it likely occurs in more. These findings may aid in developing a blood test to diagnose cancer at early stages, when it is most treatable.
Among patients treated for oropharyngeal cancers linked to human papillomavirus (HPV) infection, at least 1 HPV-infection antibody could help identify those patients at risk for a recurrence of the cancer.
A new clinical practice guideline on the appropriate use of tests for breast tumor biomarkers was issued by ASCO.
Gatastatin, an inhibitor specific for γ-tubulin, known to be overexpressed in some cancer cells, has been identified and holds potential for the development of anticancer agents.
Prognosis for patients with cutaneous melanoma may be predicted by an inherited genetic marker providing a personalized tool to gauge a person's survival and determine if closer monitoring is needed in the years following surgery.
Researchers identified a biomarker that detects the most common type of lung cancer in its earliest stage. The discovery could one day change how long lung cancer patients live.
TARC levels correlated with PET-normalization in certain patients with Hodgkin lymphoma treated with brentuximab vedotin, a study indicates.
To test thyroid malignancy, many biomarkers are tested separately to confirm cancer. However, new research shows that the tests used to measure 2 major biomarkers in the diagnosis of thyroid cancer may be inaccurate.
A team of scientists has reported that the genetic biomarker LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer. The findings present a new tool that could be used to identify patients most likely to benefit from chemoprevention.
The protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in patients with breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|